TY - JOUR T1 - Research news in clinical context JF - Sexually Transmitted Infections JO - Sex Transm Infect SP - 392 LP - 393 DO - 10.1136/sextrans-2021-055337 VL - 98 IS - 5 AU - Rayner K J Tan AU - Marina Daskalopoulou AU - Rebecca Thomson-Glover Y1 - 2022/08/01 UR - http://sti.bmj.com/content/98/5/392.abstract N2 - Tenofovir disoproxil fumarate (TDF) and intramuscular depot medroxyprogesterone acetate (DMPA-IM) are independently associated with bone loss.1 2 This cohort study conducted in Uganda in 2016–2017 assessed the combined effects of DMPA-IM and TDF initiation on bone mineral density (BMD) in women aged 18–35.3 Participants (n=521) were classified based on HIV status, TDF use and DMPA-IM use. Compared with use of TDF alone, concurrent use of DMPA-IM resulted in greater BMD decline over 24 months at all sites (–2.677% for lumbar spine, –2.518% for total hip and –2.907% for femoral neck) after adjusting for age, body mass index and baseline BMD (p<0.0001 for all). While fracture risk could not be assessed, contraception choice and bone-sparing antiretroviral therapy options for women living with HIV need to be prioritised.This follow-up study of a 3-year international, randomised trial of the quadrivalent human papillomavirus (HPV) vaccine investigated the durability of protection in men aged 16–26 years at the time of vaccination.4 Ten years on, compared with placebo, there were no new HPV 6-related or HPV 11-related cases of … ER -